Delivery Order SPE2DB22D2206-SPE2DB26FDV76
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 25, 2025, by the Defense Logistics Agency to supply Ozempic 2 mg/dose (8 mg/3 ml) injectable medication. The contract, valued at $14,490.85, represents a firm fixed price delivery order with an ultimate completion date of August 26, 2025. This award was not designated as a set-aside contract and was competitively awarded through open competition. The...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 5, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract, valued at $11,989.73, carries a firm fixed price and is classified as a non-set-aside, competitively awarded procurement. The delivery order is scheduled for completion by September 8, 2025, with the place of performance...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 19, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL injections valued at $7,156.00. The award was made by the Defense Logistics Agency under a firm fixed-price contract structure with no set-aside designation, indicating competitive award status. The order is scheduled for completion by August 20, 2025, with performance at...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on October 30, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This is a firm fixed-price, competitively awarded contract with a ceiling value of $1,204.23 and an ultimate completion date of October 31, 2025. The award carries no set-aside designation. This delivery order is issued under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 30, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $2,870.86 and is scheduled for completion by July 31, 2025. The award represents a child contract action under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on August 8, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This firm fixed-price delivery order, valued at $3,138.37, was competitively awarded without set-aside designation and is scheduled for completion by August 11, 2025. The order will be fulfilled from the vendor's location in Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on October 30, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $28,295.68. The contract is structured as a firm fixed price delivery order with an ultimate completion date of October 31, 2025, and was competitively awarded without set-aside designation. This delivery order is issued under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 27, 2025, valued at $8,937.86 for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials. This competitive, non-set-aside contract is funded through the Defense Logistics Agency's Medical Supply Chain division and is set to be completed by August 28, 2025. The delivery order will be fulfilled at AmerisourceBergen's corporate office location in...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 20, 2025, by the Defense Logistics Agency for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL quantities, with a contract value of $11,350.99 and an ultimate completion date of August 21, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded through competitive procurement. The award represents a child order under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order valued at $36,378.29 for Ozempic 2 mg/dose (8 mg/3 mL) 3 mL vials from the Defense Medical Supply Chain on July 28, 2025. The contract is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, and was awarded on a competitive basis without set-aside designation. This delivery order represents a child contract executed under...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB26FDV76Delivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on October 30, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials. The contract is valued at $15,565.13 with a firm fixed price structure and an ultimate completion date of October 31, 2025. This award represents a non-competitive, non-set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is located in Conshohocken, Pennsylvania. This delivery order supports the federal government's pharmaceutical supply requirements, specifically for the antidiabetic medication Ozempic, which is distributed to military and veteran healthcare systems through the Defense Health Agency. AmerisourceBergen's substantial IDC vehicle with DLA enables the company to supply a comprehensive range of pharmaceutical products and medical commodities to support military healthcare programs globally. The firm's demonstrated capability to fulfill federal medical procurement requirements, combined with its extensive portfolio of brand-name and generic medications across multiple therapeutic domains, positions it as a critical vendor within the DLA Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.6k | 10/30/25 |